PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 21, 2024IJC Heart & VasculatureOpen Access

The safety and efficacy of compression therapy in patients with stable heart failure

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Compression therapy is widely used for edema, but concerns exist regarding its safety in patients with heart failure due to increased venous return potentially increasing pulmonary artery blood pressure.

Does compression therapy improve symptoms and reduce BNP safely in patients with stable chronic heart failure?

Population

101 patients with stable chronic HF initiating compression therapy for lower extremity edema

Design

Retrospective cohort study

Follow-up

1 month

Key result

Compression therapy in patients with stable chronic heart failure significantly reduced NYHA III prevalence from 53.5% at baseline to 32.6% at 1 month (p<0.001), without adverse events.

Authors

TNTakahito NasuSMShingo MatsumotoWFWataru Fujimoto

Discussion

Loading...

Member takes

Overview

Supports cautious use for edema in stable chronic HF; leaves open confirmation via randomized trials.

Study Design

Type

Cohort (n=101)

Structured PICO

Does compression therapy improve symptoms and reduce BNP safely in patients with stable chronic heart failure?

P
Population
101 patients with stable chronic heart failure and lower extremity edema who initiated compression therapy, evaluated at 1 month.
E
Exposure
Compression therapy for lower extremity edema
O
Outcome
New York Heart Association (NYHA) class changes and adverse events after 1 month of compression therapypatient reported

Main Result

Absolute Event Rate: 32.6% vs 53.5%

p-value: p=<0.001

Compression therapy appears safe and is associated with improved symptoms and reduced BNP levels in patients with stable chronic heart failure, particularly those with HFpEF.

Cite This Study

Nasu et al. (2024) conducted a cohort in Stable chronic heart failure with lower extremity edema (n=101). Compression therapy vs. Baseline was evaluated on New York Heart Association (NYHA) class changes after 1 month (p=<0.001). Compression therapy in patients with stable chronic heart failure significantly reduced NYHA III prevalence from 53.5% at baseline to 32.6% at 1 month (p<0.001), without adverse events.

synapsesocial.com/papers/6aa03cc636ea76a62dc11b5ehttps://doi.org/10.1016/j.ijcha.2024.101343
View Full Paper
Ask AI
Bookmark
Share